Johnson & Johnson Reports Q1 2026 Revenue of $24.1 Billion, Raises Full-Year Outlook Toward $100.8 Billion

Recently (April 15), Johnson & Johnson announced its Q1 2026 report, achieving growth in this quarter driven by the two major sectors of innovative drugs and medical technology.Revenue of $24.1 billion, performing brilliantly and exceeding expectations.

Image Source: Johnson & Johnson Official Website

01

Cardiovascular Leader

Raise Full-Year Performance Forecast

Overall, Johnson & Johnson's two major business segments performed steadily in the Q1 of 2026.Medical technology segment achieves revenue of $8.636 billion, a year-on-year increase of 7.7%., accounting for approximately 36% of the company's total revenue, continuing the stable pattern from 2025; the innovative drug sector reached 15.426 billion USD, increasing by 11.2% year-on-year, also demonstrating robust growth resilience.

Image Source: Johnson & Johnson Official Website

Based on the strong growth trend,Johnson & Johnson Raises Full-Year Outlook, Predicting Revenue of $100.8 Billion, a 7% IncreaseIf expectations are met, Johnson & Johnson's performance in 2026 is expected to break the $100 billion mark for the first time.

Specifically, in Johnson & Johnson's medical technology segment, the cardiovascular business is its brightest growth engine. According to the financial report information released by Johnson & Johnson, in the Q1 quarter, the global operational sales of the medical technology segment increased by 4.6%, with the main driver of growth being...Derived from its three major product lines: electrophysiology products, Abiomed, and Shockwave, as well as trauma products in the orthopedics field., star products continue to drive overall growth and are the core force in the medical technology sector.

Moreover, this growth trend can also be seen in the financial report data released by Johnson & Johnson in 2025. Throughout 2025, Johnson & Johnson's cardiovascular business achieved a growth of 15.8%, with sales reaching $8.928 billion, making it the most robustly growing division among Johnson & Johnson Medical’s four major business units. Among them, electrophysiology products and Abiomed both demonstrated strong growth trends, consistent with the core growth drivers of Johnson & Johnson Medical in the Q1 quarter.

The good development of the cardiovascular business is also closely related to Johnson & Johnson's series of acquisitions in recent years. From 2022 to 2024, Johnson & Johnson Medical repeatedly invested heavily to pave the way for its cardiovascular business.Investing over $30 billion to acquire four cardiovascular device companies within three years.

Source: Compiled from public information

Thanks to various acquisitions and Johnson & Johnson's accelerated innovation and R&D efforts, cardiovascular business has now become the fastest-growing and most potential business line in its medical technology sector.

Moreover, from the growth trend of the orthopedics business segment in 2025, although the overall business maintains growth, the growth rate still lags significantly behind cardiovascular, ophthalmology, and surgical businesses. To systematically enhance the company's overall growth rate and profit margin, Johnson & Johnson announced in October 2025 that it wouldDePuy Synthes, the orthopedics business, splits into an independent company, and plans to complete the spin-off within the next 18 to 24 months.

02

Strategic Restructuring

R&D Investment Continues to Increase

In recent years, Johnson & Johnson has undergone a strategic transformation, divesting its orthopedics business and refocusing its original four segments into three core sectors: cardiovascular, surgical, and vision.Since January 1 this year, Johnson & Johnson has also undergone a major reorganization.。

Johnson & Johnson globallyShifting from a regional model to a business unit-led operational modelThis move abandons the previously traditional regional operation model, shifting globally to a new structure led by business units. This adjustment marks a decisive step for Johnson & Johnson in enhancing organizational agility, deepening professional focus, and accelerating market responsiveness.

Department AdjustmentThe Surgical and Electrophysiology divisions will establish independent regional leadership structures, with both business units reporting directly to their respective division presidents. The regional supply chain team is also undergoing a transformation, led by Luis Roman, Vice President of Medical Technology Supply Chain, to whom they will report. Additionally, Johnson & Johnson plans to gradually adjust the existing structure of its corporate functions to best support the new operating model. Meanwhile,Leadership Adjustment in Progress, and also eliminated the cross-medical technology leadership teams across various regions and markets.

Notably, Johnson & Johnson's extensive reform this time is not a "spur-of-the-moment decision." Extending the timeline, signs of the reorganization decision were already apparent by early 2024. Regarding the new model for this reorganization, Johnson & Johnson stated in an internal email that the new model will be led by business units, which will also reduce decision-making delays caused by organizational layers, strengthen the accountability and autonomy of business units, thereby improving overall execution efficiency.

Under a series of reform initiatives, the development path of Johnson & Johnson Medical Technology is also relatively clear. Mainly throughDivest low-growth businesses, focus on high-growth tracks such as cardiovascular and surgical robotics, while continuously increasing R&D investment and strategic mergers and acquisitions, systematically reshaping the growth landscape.

According to the PharmCube medical device data query,Currently, Johnson & Johnson has launched over a thousand products in the United States and more than 60 products in China., a rich product line, and Johnson & Johnson is also continuously increasing its investment in multiple细分赛道, with several promising products awaiting release. For instance, Johnson & Johnson is making a strong push into the surgical robotics arena, directly challenging the leader in the field, Intuitive Surgical. In January 2026, Johnson & Johnson submitted to the U.S. FDAOttava Robotic Surgical SystemThe De Novo classification application aims to cover various upper abdominal surgeries, including gastric bypass and hiatal hernia repair. The product is expected to be approved in 2026.

Image Source: PharmaSmart Medical Device Data

A rich product pipeline, sufficient subsequent reserves, and the rise of new forces have driven the continuous growth and steady expansion of Johnson & Johnson's three major divisions, collectively forming the core growth engine of the medical technology sector.

03

Conclusion

From the Q1 2026 financial report, Johnson & Johnson's development trajectory is clear and stable, with cardiovascular business leading growth, orthopedics divestiture proceeding orderly, and the surgical robotics pipeline approaching commercialization. With the second quarter now officially underway, can Johnson & Johnson maintain its growth trend in 2026 and achieve the much-anticipated milestone of surpassing $100 billion in revenue for the first time? We'll have to wait and see.

References: Johnson & Johnson official website, financial reports